Given the low number of injections needed per eye, the low rate of reported adverse events, and the beneficial outcome of treated patients in this cohort, we recommend administering anti-VEGF in patients with BVMD with secondary CNV in the presence of any active CNV and advising the patient of potential concurrent vision-limiting features such as subretinal fibrosis or atrophy that could limit BCVA recovery. Here, VEGFA is linked to Atrophy.